Why the big drop?, page-7

tpf3891
thanks for your bleak perspective - now here is the opposite spin.

At $800 Million with the real potential to be generating billions in revenue over the coming years (2-3) as its many applications move positively through their testing stages to commercial viability (with scope to accelerate the trials as well - see Texas Bill) .

If this so called company with the big grey cloud manages to partner with MSB in the coming weeks then watch the vermin shorters scurry about and send the price back up to where it should be i.e. north of $3.40.

There are risks but as time marches forward those risks are being reducing. The paradigm shift to stem cell therapy and treatment will be well spoken about in years to come and MSB will be hailed as the company that pioneered the change away from a heavy reliance on drugs.